Q-omics provides the consensus-scored IGHV2OR16-5 profile across patient tissues and cancer cell-line models. IGHV2OR16-5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IGHV2OR16-5 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, IGHV2OR16-5 RNA expression shows 6,234 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight KICH, LUAD, and BRCA as cancer lineages where IGHV2OR16-5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHV2OR16-5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHV2OR16-5 survival associations across molecular data types. IGHV2OR16-5 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHV2OR16-5 RNA expression–survival associations across cancer types. High IGHV2OR16-5 expression shows unfavorable associations in KICH, ACC and UCS, but favorable associations in HNSC, BRCA and LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IGHV2OR16-5 RNA expression.
This table summarizes IGHV2OR16-5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHV2OR16-5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHV2OR16-5 shows lower tumor expression in COAD, PAAD, BRCA and READ and higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher IGHV2OR16-5 RNA expression in tumor versus normal tissue (log2 FC = +0.440, t-test p < 0.001).
This table shows molecular features associated with IGHV2OR16-5 in patient tissues and cancer cell lines. In patient samples, IGHV2OR16-5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
